Immunome Inc. (IMNM)
| Bid | 6.88 |
| Market Cap | 590.18M |
| Revenue (ttm) | 13.06M |
| Net Income (ttm) | -423.04M |
| EPS (ttm) | -5 |
| PE Ratio (ttm) | -1.39 |
| Forward PE | -3.53 |
| Analyst | Buy |
| Ask | 7.21 |
| Volume | 851,661 |
| Avg. Volume (20D) | 969,150 |
| Open | 7.23 |
| Previous Close | 7.28 |
| Day's Range | 6.89 - 7.39 |
| 52-Week Range | 6.90 - 24.86 |
| Beta | 1.94 |
About IMNM
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 a...
Analyst Forecast
According to 5 analyst ratings, the average rating for IMNM stock is "Buy." The 12-month stock price forecast is $25, which is an increase of 258.68% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · businesswire.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced toda...
1 month ago · seekingalpha.com
Immunome Can Take The Fight To Competitors With VaregacestatImmunome Can Take The Fight To Competitors With Varegacestat
1 month ago · businesswire.com
Immunome Announces Pricing of Upsized Public Offering of Common StockBOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced t...
